 "Claris Injectables receives five 483s from US FDA for plant in Ahmedabad")
Claris Injectables Ltd (CIL), a wholly-owned subsidiary of the Ahmedabad-based Claris Lifesciences Ltd, has received five 483s from the US Food & Drug Administration for the plant 1 (Clarion 1) of its manufacturing facility at Charcharvadi, Vasna (Ahmedabad, Gujarat)
The company received 483s after US FDA's inspection, classified as prior approval inspection (PAI), which was conducted from August 16 to August 26, 2016.
A Form 483 is issued by US FDA for violations of current good manufacturing practices which if unaddressed can lead to a warning letter or import alert by the regulator.
"The company has received five 483s during the inspection, it is confident to reply to these within 15 business days, with corrective and preventive actions to address the same,” said Claris Lifesciences in a BSE filing on August 26, 2016.
According to the company, PAI inspections are part of a normal course of business to approve the under approval ANDAs. Claris currently has 24 ANDAs under approval with a total addressable market size of the under approval products estimated to be around $ 2 billion.
CIL, which focuses on specialty injectables, manufactures products across multiple delivery systems, markets and therapeutic segments including anaesthesia, blood products, anti-infectives and plasma volume expanders.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%